Complement Inhibition Slows GA in Eyes With Wet AMD

A retrospective analysis presented at ASRS 2025 shows a sharply reduced lesion growth rate and stable CNV activity in treated eyes.

By: Jim Gallagher, senior managing editor

Retinal Physician August 2, 2025 Vol 22, Issue July/August 2025

1

Complement inhibition therapy significantly reduced geographic atrophy progression by nearly 50% in wet AMD patients.
2

The study involved a retrospective review of 33 eyes treated with pegcetacoplan or avacincaptad pegol.
3

Post-treatment, the annual rate of GA lesion growth declined from 1.5 mm² to 0.8 mm².
4

Only 4 eyes showed new signs of choroidal neovascularization, with minimal impact on anti-VEGF treatment regimens.
5

Visual acuity remained stable over the 1-year follow-up, indicating no significant decline in patient vision.

1